Evidence map›Paper›PMID 31452083›Full record

ArticleHuman cell2019

MicroRNA-532 exerts oncogenic functions in t(4;14) multiple myeloma by targeting CAMK2N1.

Kaihong Xu, Xuezhen Hu, Laifang Sun, Qingyue Liang, Guifang Ouyang, Yanli Zhang, Qitian Mu, Xiao Yan

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kaihong XuDepartment of Hematology, Ningbo First Hospital, No. 59 Liuting Street, Ningbo, Zhejiang, 315000, China. KaihongXu198@163.com.
Xuezhen HuDepartment of Emergency Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Laifang SunDepartment of Emergency Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Qingyue LiangDepartment of Nutrition, The Second Clinical Medical College of Chengdu University of Traditional Chinese Medicine, Guangan, Sichuan, 638500, China.
Guifang OuyangDepartment of Hematology, Ningbo First Hospital, No. 59 Liuting Street, Ningbo, Zhejiang, 315000, China.
Yanli ZhangDepartment of Hematology, Ningbo First Hospital, No. 59 Liuting Street, Ningbo, Zhejiang, 315000, China.
Qitian MuDepartment of Hematology, Ningbo First Hospital, No. 59 Liuting Street, Ningbo, Zhejiang, 315000, China.
Xiao YanDepartment of Hematology, Ningbo First Hospital, No. 59 Liuting Street, Ningbo, Zhejiang, 315000, China.
Ningbo First Hospital · CNSecond Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University · CNChengdu University of Traditional Chinese Medicine · CN

Funding

Natural Science Foundation of Ningbo Municipality 2017A610210
6 · The paper itself

Abstract

Multiple myeloma (MM) is a plasma cell neoplasm which is characterized by widespread genetic heterogeneity. The MMs with t(4;14) translocation exhibit poor outcomes. However, the mechanism underlying has not been well dissected. Our study aimed to identify key microRNA involved in the oncogenesis of t(4;14) MM. We here performed an integrated analysis to screen important regulators in the pathogenesis of t(4;14) MM. We used real-time quantitative polymerase chain reaction and western blotting to evaluate the mRNA and protein expression of the indicated microRNA or protein. Cell proliferation assay, colony formation assay, and transwell assay were used to examine the cell growth and metastasis. More importantly, the tumor growth and metastasis were analyzed in nude mice injected with MM cells. The integrated analysis indicated that miR-532 functioned as a pivotal regulator in t(4;14) MM. miR-532 was upregulated in t(4;14) MMs and promotes cell growth and metastasis in vitro and in vivo. Notably, though combing bioinformatics analysis and functional assays, CAMK2N1 was revealed as a functional target of miR-532 in MM cells. CAMK2N1 plays an anti-proliferative and anti-migration role in MM cells, and miR-532 exerts its oncogenic role though inhibiting CAMK2N1 expression in MMs. miR-532 promotes cell proliferation and invasion in t(4;14) MMs by targeting CAMK2N1. Our study, thus, provides possible targets for t(4;14) MM therapy.

Indexed as

CarcinogenesisCell Line, TumorCell MovementCell ProliferationGene ExpressionHumansMicroRNAsMolecular Targeted TherapyMultiple MyelomaNeoplasm InvasivenessProteinsTranslocation, GeneticUp-RegulationCAMK2N1 protein, humanMicroRNAsMIRN532 microRNA, humanProteinsCAMKmiR-532Multiple myelomat(4;14)

Identifiers

PMID31452083
OpenAlexW2971118157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.